BioTime reports additional data for Renevia facial lipoatrophy device

By Meghan Sullivan | Oct 6, 2017 | 7:37 PM GMT

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy